These effects, together with the induced TGF-β release in very low amounts, might result in an overall anti-tumoral response, thus supporting the clinical use of vitamin D in PDAC patients, even if pancreatic cancer cells appear insensitive to vitamin D treatment. This evidence concerns the gene TGFB1 and pancreatic neoplasm.